Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2021

View Archived Issues

British Pakistani genomics study illustrates need for diversity

Engineered AAV capsids allow specific transgene expression in the brain of mouse and marmoset

Alphataxin increases CD4+ tumor-infiltrating T cells and suppresses renal cell cancer in mice

Dual PI3K/BRD4 inhibitors divulged by Monash University, Peter MacCallum Cancer Centre

CSIPI and Shanghai Zhongze Therapeutics patent dopamine D2/D3/5-HT2A receptor antagonists

Trinuero, DGMIF identify SERT, NET and DAT inhibitors

Janssen Pharmaceutica synthesizes new Mcl-1 inhibitors

New USP30 inhibitors identified at Mission Therapeutics

Anti-CD47 antibody ADG-153 shows promising preclinical data for cancer immunotherapy

Gene expression of extramedullary multiple myeloma samples points to new targets

Evusheld retains neutralizing activity against Omicron variant

WestVac BioPharma's COVID-19 vaccine shows high titer neutralizing antibodies against Omicron

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...